ARTICLE | Clinical News
MGI Pharma to start pancreatic cancer Phase III
October 23, 2000 7:00 AM UTC
MOGN said it will begin by year end U.S. Phase III testing of its Irofulven hydroxymethylacylfulvene ( MGI 114) compound in patients with advanced pancreatic cancer with disease progression following ...